Professor Ashok Venkitaraman
![]() |
University positionUrsula Zoellner Professor; Director, MRC Cancer Cell Unit Professor Ashok Venkitaraman is pleased to consider applications from prospective PhD students. |
DepartmentsMRC Cancer Cell Unit and Department of Oncology InstitutesMedical Research Council Cancer Cell Unit and Hutchison/Medical Research Council Research Centre |
Home pagehttp://www.mrc-ccu.cam.ac.uk/... Research ThemesCancer biology and in vivo models Experimental therapeutics / drug discovery |
Interests

View image full-size
Human cancer cells almost always contain abnormal chromosomes, yet the connections between chromosomal instability and carcinogenesis are poorly understood. Our laboratory aims not only to understand how cells maintain normal chromosome structure and number, and why maintenance should break down in cancer cells, but also to translate this knowledge to improvements in cancer diagnosis and treatment. We employ a wide range of approaches from molecular cell biology and somatic cell genetics, to structural biology, biophysics, imaging and chemical biology.
We actively translate molecular insights from our studies to clinical practice. In particular, we participate in The Cambridge Molecular Therapeutics Programme, a multidisciplinary effort that aims to pioneer innovative new approaches for the discovery and early clinical development of small molecule drugs against cancer.
Research Focus
Keywords
Cancer sites
Equipment
Key publications
Skoulidis F, Cassidy L, Pisupati V, Jonasson J, Eyfjord J, Kerreth F, Lim M, Olive K, Tuveson D, Venkitaraman AR (2010), “Germline Brca2 heterozygosity promotes KrasG12D-driven carcinogenesis in a murine model of familial pancreatic cancer”, Cancer Cell 18:499–505
Garnett M, Mansfeld J, Godwin C, Matsusaka T, Wu J, Russell P, Pines J, Venkitaraman AR (2009), “UBE2S elongates ubiquitin chains on APC/C substrates to promote mitotic exit”, Nature Cell Biol 11:1363–69
Ayoub NA, A D, Devaprasath JA, Bernal AR, Venkitaraman (2008), “HP1-beta mobilization promotes chromatin changes that initiate the DNA damage response”, Nature 453: 682 6:
Collaborators
Cambridge
Chris Abell
Shankar Balasubramanian
Tom Blundell
Mike Payne



